CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by aberrant immune responses.
• The role of CD47, a transmembrane protein, in SLE pathogenesis remains incompletely understood.
• Investigating CD47's function is crucial for developing targeted therapies for SLE.

Purpose of the Study:

• To elucidate the role of CD47 in the inflammatory processes of SLE.
• To examine CD47 and SIRPα expression in SLE patients' peripheral blood mononuclear cells (PBMCs).
• To assess the impact of SLE serum and inflammatory cytokines on CD47 expression.

Main Methods:

• Monocytes and THP1 cells were stimulated with LPS, anti-CD47 antibody, or both to measure TNF-α production.
• CD47 expression on PBMCs was analyzed using flow cytometry.
• Sera from SLE patients and healthy controls (HCs) were screened for anti-CD47 autoantibodies.

Main Results:

• CD47 expression on monocytes was significantly higher in SLE patients compared to HCs (p < 0.001).
• Monocyte CD47 expression correlated positively with SLE disease activity (p = 0.019).
• Anti-CD47 antibodies were found at higher levels in SLE patients (p = 0.02).

Conclusions:

• CD47 is upregulated on monocytes in SLE and is associated with disease severity.
• CD47 signaling contributes to heightened inflammatory responses in SLE.
• Targeting CD47 presents a potential novel therapeutic avenue for SLE management.